肿瘤突变负荷可预测微卫星高度不稳定转移性结直肠癌对免疫检查点抑制剂的应答
在五个中心接受PD-1/L1抑制剂治疗的22例经杂交捕获NGS确认的MSI-H转移性结直肠癌患者中,TMB与客观缓解和PFS独立相关,最佳预测界值约37-41突变/Mb,TMB高者全部缓解而TMB低者多数进展;在18,140例CRC大样本中该界值对应第35百分位。
要点
- TMB与MSI-H转移性结直肠癌患者PD-1/L1抑制剂的客观缓解和PFS独立相关。
- TMB最佳预测界值约37-41突变/Mb,13例TMB高者全部缓解,9例TMB低者中6例进展。
- TMB高者中位PFS未达到(中位随访>18个月),TMB低者为2个月。
核心结论
- TMB似乎是MSI-H转移性结直肠癌中独立的重要生物标志物,可用于分层患者对免疫检查点抑制剂获得应答的可能性。
- 若在前瞻性研究中得到验证,TMB可能对指导MSI-H转移性结直肠癌中免疫检查点抑制剂的序贯和/或联合治疗发挥重要作用。
研究设计与样本
- 多中心研究,收集五个中心经杂交捕获NGS确认的MSI-H转移性结直肠癌并接受PD-1/L1抑制剂治疗患者的临床病理资料。
- TMB在0.8-1.1 Mb测序DNA上测定,以突变/Mb报告。
- 共22例患者接受PD-1/L1抑制剂治疗,其中19例接受帕博利珠单抗单药治疗。
- 另分析18,140例CRC患者的大样本数据以确定所识别TMB界值的相关性。
主要发现
- 在检测的变量中,TMB与客观缓解(P < 0.001)及PFS在单变量(P < 0.001)和多变量分析(P < 0.01)中相关性最强。
- 采用log-rank统计,TMB最佳预测界值估计在37-41突变/Mb之间。
- 13例TMB高者全部缓解,9例TMB低者中6例出现疾病进展。
- TMB高者中位PFS未达到(中位随访>18个月),TMB低者中位PFS为2个月。
- 在经NGS评估的大样本MSI-H转移性结直肠癌人群(821/18,140例;4.5%)中,37.4突变/Mb对应第35百分位界值。
关键数值与推荐
- TMB最佳预测界值估计在37-41突变/Mb之间(采用log-rank统计)。
- 大样本MSI-H转移性结直肠癌中37.4突变/Mb对应第35百分位界值。
- TMB与客观缓解相关P < 0.001,与PFS单变量分析P < 0.001、多变量分析P < 0.01。
临床怎么用
- 原文结论认为若在前瞻性研究中得到验证,TMB可能对指导MSI-H转移性结直肠癌中免疫检查点抑制剂的序贯和/或联合治疗发挥重要作用。
局限性
- 原文指出帕博利珠单抗和纳武利尤单抗报告的应答率多变且常<50%,提示需要额外的预测性生物标志物。
- 原文结论提出TMB若在前瞻性研究中得到验证才可能发挥指导作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Microsatellite instability (MSI) is a biomarker for response to immune checkpoint inhibitors (ICPIs). PD-1 inhibitors in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated a high disease control rate and favorable progression-free survival (PFS); however, reported response rates to pembrolizumab and nivolumab are variable and often <50%, suggesting that additional predictive biomarkers are needed. METHODS: Clinicopathologic data were collected from patients with MSI-H mCRC confirmed by hybrid capture-based next-generation sequencing (NGS) treated with PD-1/L1 inhibitors at five institutes. Tumor mutational burden (TMB) was determined on 0.8-1.1 Mb of sequenced DNA and reported as mutations/Mb. Potential biomarkers of response and time to progression were analyzed by univariate and multivariate analyses. Once TMB was confirmed as a predictive biomarker, a larger dataset of 18 140 unique CRC patients was analyzed to define the relevance of the identified TMB cut-point. RESULTS: A total of 22 patients were treated with PD-1/L1 inhibitors including 19 with pembrolizumab monotherapy. Among tested variables, TMB showed the strongest association with objective response (OR; P < 0.001) and PFS, by univariate (P < 0.001) and multivariate analysis (P < 0.01). Using log-rank statistics, the optimal predictive cut-point for TMB was estimated between 37 and 41 mutations/Mb. All 13 TMBhigh cases responded, while 6/9 TMBlow cases had progressive disease. The median PFS for TMBhigh has not been reached (median follow-up >18 months) while the median PFS for TMBlow was 2 months. A TMB of 37.4 mutations/Mb in a large MSI-H mCRC population (821/18, 140 cases; 4.5%) evaluated by NGS corresponded to the 35th percentile cut-point. CONCLUSIONS: TMB appears to be an important independent biomarker within MSI-H mCRC to stratify patients for likelihood of response to ICPIs. If validated in prospective studies, TMB may play an important role in guiding the sequencing and/or combinations of ICPIs in MSI-H mCRC.
引用
- Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019. PMID: 31038663. doi:10.1093/annonc/mdz134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。